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To the Editor: We read with interest the recent article by
Serra et al.1 detailing a variety of glomerular lesions
(increased mesangial matrix, mesangial cell proliferation,
podocyte hypertrophy, and glomerulomegaly) in extremely
obese patients without clinical signs of renal dysfunction.
Despite using a broad array of clinical and biochemical
variables in their regression models, only body mass index
was found to be a significant predictor of glomerular lesions
in multivariate analysis.
We believe that serum aldosterone, if included in the
analysis, would have likely emerged as another important
predictor of obesity-related renal damage. Obesity is
frequently associated with elevated levels of aldosterone.2 In
the obese state, oxidized fatty acids likely stimulate
aldosteronogenesis;3 in vitro, human adipocytes secrete
potent mineralocorticoid-releasing factors.4 Aldosterone is
important in salt and water balance by acting on epithelial
mineralocorticoid receptors, but its effects through miner-
alocorticoid receptors in nonepithelial tissues may be more
important in the pathogenesis of chronic kidney disease. In
animal models, unopposed aldosterone in the presence of
high salt intake causes thrombotic and proliferative lesions in
the glomeruli and renal vessels.5–7 These pathologic lesions
occur independent of blood pressure, reflecting a direct,
nonepithelial, profibrotic effect of aldosterone on the kidney.
The increased glomerulosclerosis in these hyperaldoster-
one models typically result in severe proteinuria, a distinctly
different phenotype from Serra et al.’s extremely obese
subjects whose clinical renal function was normal. The
authors, however, argue that the early lesions found in this
study are potential harbingers of future, overt kidney disease.
If so, then the glomerular lesions described in this study will
likely progress to the more sclerotic lesions typified in the
seminal animal studies discussed above.
The role of aldosterone in obesity-related kidney injury
becomes more important as the discussion shifts toward
potential treatment options. Serra et al. admit that their study
does not address whether bariatric surgery could reverse the
renal lesions seen on biopsy, and the authors cite a study in
which angiotensin-converting enzyme inhibitors and statins
ameliorate podocyte damage in obese rats.8 In dogs fed a
high-fat diet, the use of an aldosterone antagonist (compared
to untreated controls) markedly attenuated obesity-induced
glomerular hyperfiltration, sodium retention, and hyperten-
sion.9 Because it will not be possible to offer all extremely
obese patients bariatric surgery, it may be beneficial to check
these patients’ aldosterone levels and, if elevated, prescribe
mineralocorticoid receptor blockers and salt restriction for
renal protection. Alternatively, empiric treatment with
mineralocorticoid receptor blockers and a low-salt diet may
be undertaken even without aldosterone measurement,
recognizing the possibility that mineralocorticoid receptor
activation may also occur by elevated cortisol concentrations
in obesity.10
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We appreciate the comments of Dr Bomback and Dr
Klemmer on the possible relationship between aldosterone
and obesity-related renal lesions.1
Obesity is associated with elevated levels of several
hormones including aldosterone, leptin, adiponectin,
cortisol, renin, and angiotensin.2,3 Some of these
hormones, such as leptin, have been associated with
the production of renal lesions in animal models.4
l e t t e r t o t h e e d i t o r http://www.kidney-international.org
& 2008 International Society of Nephrology
1216 Kidney International (2008) 74, 1216–1217
